Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

71.40 +1.37 (+1.96%)
Streaming Delayed Price Updated: 1:52 PM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Why I Keep Buying These 10 Incredible Growth Stocks ↗
These companies have bright futures and offer the potential for decades of share price appreciation. 
Via The Motley Fool
Topics Energy
News headline image
Halozyme Therapeutics Inc (NASDAQ:HALO) Embodies Affordable Growth with Strong Metrics ↗
Halozyme Therapeutics offers strong growth and profitability at a reasonable valuation, making it a top Affordable Growth stock pick. 
Via Chartmill
News headline image
Halozyme Therapeutics Inc (NASDAQ:HALO) Shows Strong Technical and Fundamental Momentum ↗
Halozyme (HALO) stock shows a powerful uptrend with strong technicals and high-growth fundamentals, including surging earnings and sales. 
Via Chartmill
News headline image
Halozyme Stock Surging On Recent Earnings Beat; Record High Ahead? ↗
Halozyme also boasts a 98 Composite Rating out of 99. The best growth stocks have a Composite of 90 or better. 
Via Investor's Business Daily
News headline image
Halozyme Therapeutics Inc (NASDAQ:HALO) Shows Strong Growth and Technical Breakout Potential ↗
Discover Halozyme (HALO), a biotech stock with strong EPS growth, high profitability, and a bullish technical breakout pattern for potential gains. 
Via Chartmill
News headline image
Earnings Scheduled For November 3, 2025 ↗
 
Via Benzinga
News headline image
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025.... 
Via MarketMinute
Topics Intellectual Property
News headline image
Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look ↗
Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Halozyme (HALO) Q3 2025 Earnings Call Transcript ↗
Halozyme (HALO) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Insights into Halozyme Therapeutics's Upcoming Earnings ↗
 
Via Benzinga
News headline image
Halozyme Therapeutics Inc (NASDAQ:HALO) Fits a Proven Growth Investing Method ↗
Halozyme Therapeutics shows strong growth metrics, including soaring earnings, sales, and a high ROE, fitting a proven growth investing strategy. 
Via Chartmill
News headline image
Koa Wealth Liquidates All 68K IIPR Shares Valued at $3.8 Million ↗
Koa Wealth Liquidates All 68K IIPR Shares Valued at $3.8 Million 
Via The Motley Fool
Topics Cannabis
News headline image
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Combines Strong Growth Momentum with Technical Breakout Setup ↗
Halozyme Therapeutics (HALO) offers a high-growth momentum play with strong earnings, rising profit margins, and a technical breakout setup for potential entry. 
Via Chartmill
News headline image
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Value Investment Case ↗
Halozyme Therapeutics (HALO) is a strong value stock with high profitability, a healthy balance sheet, and solid growth, all while trading at an attractive valuation. 
Via Chartmill
News headline image
Halozyme Therapeutics Inc (NASDAQ:HALO) Offers an Affordable Growth Profile ↗
Halozyme Therapeutics offers strong growth and profitability at an attractive valuation. Its ENHANZE drug delivery tech drives revenue, with a low P/E ratio for an affordable growth stock. 
Via Chartmill
News headline image
Halozyme Therapeutics Inc (NASDAQ:HALO): A Growth Stock Poised for a Breakout ↗
Halozyme Therapeutics offers strong growth with high profitability and a positive technical setup, making it a compelling biotech stock to watch. 
Via Chartmill
News headline image
The Analyst Verdict: Halozyme Therapeutics In The Eyes Of 10 Experts ↗
 
Via Benzinga
News headline image
Halozyme Therapeutics Inc (NASDAQ:HALO) Demonstrates Strong Growth and Profitability ↗
Discover Halozyme Therapeutics, a top growth stock with strong earnings, soaring revenue, and high profitability. A prime example of the Navellier investing method. 
Via Chartmill
News headline image
Halozyme Therapeutics Inc (NASDAQ:HALO): A Prime Candidate for Affordable Growth ↗
Halozyme Therapeutics (HALO) offers strong growth, high profitability, and an attractive valuation, making it a compelling GARP (Growth at a Reasonable Price) investment candidate. 
Via Chartmill
News headline image
Forecasting The Future: 7 Analyst Projections For Halozyme Therapeutics ↗
 
Via Benzinga
News headline image
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a High-Growth Momentum and Technical Breakout Opportunity ↗
Halozyme Therapeutics is a high-growth biotech stock with strong earnings, revenue momentum, and a bullish technical setup nearing a breakout. 
Via Chartmill
News headline image
Halozyme Therapeutics Inc (NASDAQ:HALO) Embodies Navellier's Growth Investing Principles ↗
Discover Halozyme (HALO), a top growth stock with strong earnings surprises, soaring revenue, and exceptional profitability, fitting Navellier's proven investment strategy. 
Via Chartmill
News headline image
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Case for Value Investors ↗
Halozyme (HALO) presents a strong value investing case with low P/E ratios, robust financial health, high profitability, and solid growth, suggesting it trades below its intrinsic value. 
Via Chartmill
News headline image
United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results ↗
United Therapeutics also boasts a terrific 96 Composite Rating. The Composite score combines five separate proprietary ratings into one. 
Via Investor's Business Daily
Topics ETFs
News headline image
Halozyme Therapeutics Inc (NASDAQ:HALO) Fits Minervini's Trend Template with Strong Technicals and Earnings Momentum ↗
Halozyme Therapeutics (HALO) exemplifies Mark Minervini's Trend Template, combining a strong technical uptrend with accelerating earnings growth and expanding profit margins. 
Via Chartmill
News headline image
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Offers Affordable Growth With Strong Fundamentals ↗
Discover HALOZYME (HALO), an affordable growth stock with strong profitability, solid financials, and a reasonable valuation. 
Via Chartmill
News headline image
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Stands Out in Navellier's Growth Screen ↗
HALOZYME (HALO) exemplifies Louis Navellier's growth investing strategy with strong sales growth, soaring earnings, high ROE, and consistent positive earnings surprises. 
Via Chartmill
News headline image
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded ↗
Additionally, the IBD SmartSelect Composite Rating for Argenx stock rose from 94 to a near best 96 Tuesday. 
Via Investor's Business Daily
Topics ETFs
News headline image
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Stands Out as a Top Undervalued Stock with Strong Fundamentals ↗
Discover HALOZYME (HALO), a top value investing pick. It boasts a strong Valuation Rating of 9, high profitability, and robust growth, making it a fundamentally sound yet undervalued stock. 
Via Chartmill
News headline image
What 7 Analyst Ratings Have To Say About Halozyme Therapeutics ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.